Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO OTCMKTS:CYDY NASDAQ:GBT NASDAQ:NKTR NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$0.48-2.9%$0.48$0.40▼$8.78$25.77M1.11922,862 shs272,363 shsCYDYCytoDyn$0.32-1.0%$0.34$0.10▼$0.49$394.23M1.173.03 million shs972,342 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsNKTRNektar Therapeutics$25.01-0.4%$13.94$6.48▼$37.38$310.30M0.94501,223 shs1.21 million shsPCRXPacira BioSciences$22.90-3.3%$24.88$11.16▼$27.64$1.06B0.48902,506 shs504,334 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-0.66%+5.74%-6.89%+1.43%-92.65%CYDYCytoDyn+1.79%+11.65%-10.14%+51.52%+127.51%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics+7.45%+1.83%+121.15%+170.90%+25.81%PCRXPacira BioSciences+2.24%+2.09%-4.74%-3.54%+16.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALXOALX Oncology2.8264 of 5 stars3.41.00.00.01.14.21.3CYDYCytoDynN/AN/AN/AN/AN/AN/AN/AN/AGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANKTRNektar Therapeutics4.8258 of 5 stars4.45.00.04.23.12.50.0PCRXPacira BioSciences3.3681 of 5 stars2.22.00.03.91.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.71Moderate Buy$3.30583.94% UpsideCYDYCytoDyn 0.00N/AN/AN/AGBTGlobal Blood Therapeutics 0.00N/AN/AN/ANKTRNektar Therapeutics 2.86Moderate Buy$88.33253.19% UpsidePCRXPacira BioSciences 2.33Hold$26.4415.48% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, ALXO, NKTR, CYDY, and GBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $85.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.005/21/2025ALXOALX OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/12/2025NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform5/9/2025ALXOALX OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.005/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.004/11/2025NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.00 ➝ $30.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/ACYDYCytoDynN/AN/AN/AN/A($0.11) per shareN/AGBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46NKTRNektar Therapeutics$87.25M3.56N/AN/A$4.94 per share5.06PCRXPacira BioSciences$700.97M1.51$4.26 per share5.37$16.86 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$134.85M-$2.47N/AN/AN/AN/A-104.43%-77.74%8/14/2025 (Estimated)CYDYCytoDyn-$49.84MN/A0.00∞N/AN/AN/A-33.26%8/13/2025 (Estimated)GBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/ANKTRNektar Therapeutics-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A8.91N/A-14.78%13.78%7.00%7/29/2025 (Estimated)Latest PCRX, ALXO, NKTR, CYDY, and GBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025PCRXPacira BioSciences$0.73N/AN/AN/A$183.11 millionN/A5/8/2025Q1 2025ALXOALX Oncology-$0.47-$0.58-$0.11-$0.58N/AN/A5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.095.475.47CYDYCytoDynN/A0.300.30GBTGlobal Blood Therapeutics4.926.886.17NKTRNektar TherapeuticsN/A3.243.24PCRXPacira BioSciences0.482.411.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%CYDYCytoDyn5.06%GBTGlobal Blood TherapeuticsN/ANKTRNektar Therapeutics75.88%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%CYDYCytoDyn0.54%GBTGlobal Blood Therapeutics4.90%NKTRNektar Therapeutics5.25%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.40 million42.18 millionOptionableCYDYCytoDyn201.25 billion1.24 billionNot OptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionableNKTRNektar Therapeutics22012.41 million11.76 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionablePCRX, ALXO, NKTR, CYDY, and GBT HeadlinesRecent News About These CompaniesPacira BioSciences to Close Manufacturing Suite, Lay Off 71 EmployeesJuly 10 at 12:27 PM | marketwatch.comPacira announces layoffs due to efficiencies in Exparel productionJuly 10 at 12:27 PM | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comRobeco Institutional Asset Management B.V. Purchases 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)July 2, 2025 | marketbeat.comPacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025June 18, 2025 | finance.yahoo.comIs the Options Market Predicting a Spike in Pacira BioSciences Stock?June 18, 2025 | zacks.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from AnalystsJune 18, 2025 | marketbeat.comPACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 17, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 14, 2025 | marketbeat.comPacira Pharmaceuticals Stockholders Approve Amended Incentive PlanJune 13, 2025 | tipranks.comPacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8, 2025 | accessnewswire.comALauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockJune 7, 2025 | insidertrades.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comPacira BioSciences’s First Quarter 2025 Misses EstimatesMay 29, 2025 | ryortho.comRBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach OutMay 25, 2025 | accessnewswire.comAPacira at RBC Conference: Strategic Growth and Gene Therapy FocusMay 23, 2025 | uk.investing.comPacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%May 22, 2025 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesMay 14, 2025 | globenewswire.comTruist Financial Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)May 11, 2025 | theglobeandmail.comEarnings call transcript: Pacira Q1 2025 shows revenue miss, stock dipsMay 10, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?PCRX, ALXO, NKTR, CYDY, and GBT Company DescriptionsALX Oncology NASDAQ:ALXO$0.48 -0.01 (-2.92%) Closing price 04:00 PM EasternExtended Trading$0.48 +0.00 (+0.52%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.CytoDyn OTCMKTS:CYDY$0.32 0.00 (-1.01%) As of 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Global Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Nektar Therapeutics NASDAQ:NKTR$25.01 -0.09 (-0.36%) Closing price 04:00 PM EasternExtended Trading$24.74 -0.28 (-1.10%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Pacira BioSciences NASDAQ:PCRX$22.90 -0.79 (-3.33%) Closing price 04:00 PM EasternExtended Trading$22.90 0.00 (-0.02%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
